Base to Base Biotech
Base to Base Biotech
Podcast Description
The Base to Base Biotech podcast is a weekly look at what's happening in the world of biotech, with interviews with biotech leaders around the world.Whether it's a new drug, cutting-edge technology, product launches, new technology, major finding announcement or clinical trial results, Base to Base Biotech keeps you informed.The podcast is hosted by former biotech editor and broadcaster, the award-winning media veteran Jim Cornall.Base to Base is an Ayr Coastal Media Ltd production.
Podcast Insights
Content Themes
The podcast covers a range of topics within the biotech realm, including new drug developments, technological advancements, clinical trial results, and product launches. Specific episodes highlight innovations like non-addictive pain alternatives and wearable devices for bone health, alongside discussions on artificial intelligence in disease diagnostics and cancer immunotherapy strategies. Each episode aims to keep listeners informed and engaged with the dynamic biotech sector.
The Base to Base Biotech podcast is a weekly look at what’s happening in the world of biotech, with interviews with biotech leaders around the world.
Whether it’s a new drug, cutting-edge technology, product launches, new technology, major finding announcement or clinical trial results, Base to Base Biotech keeps you informed.
The podcast is hosted by former biotech editor and broadcaster, the award-winning media veteran Jim Cornall.
Base to Base is an Ayr Coastal Media Ltd production.
This week, we chat with Lucas Decuypere, CEO and president of Allegro, about treatment of knee osteoarthritis with a nanotechnology injection, and Elin Trampe, the CEO of Dicot Pharma, a company developing a new form of erectile dysfunction treatment.
Times:
01:46 Dicot Pharma
17:21 Allegro
Allegro
Allegro is a Belgium-based biomedical company which recently announced statistically significant improvements in pain and function in a 30-patient study of hydrocelin, a first-in-class nanotechnology injection for knee osteoarthritis (OA).
Rather than lubricating the joint like existing injectables such as hyaluronic acid or corticosteroids, hydrocelin uses cross-linked microparticles designed to physically restore the shock-absorbing mechanics of synovial fluid, thereby targeting a proposed root cause of OA rather than just masking symptoms.
Separately, Allegro just completed enrolment in a parallel European feasibility trial two months ahead of schedule. Topline safety/tolerability data are expected in H2 2026 and will inform a planned global registrational study.
Dicot Pharma
Dicot Pharma is developing the first innovation to erectile dysfunction in last 30 years. Virtually nothing has happened since Viagra and Cialis were introduced.
The company has recently been given the green light to start its phase IIb trials in the US, and trials are about to start in the EU, too.
The drug, LIB-01 has a completely different mode of action, which means a wider group of men can take it. Taking three pills means the drug will work spontaneously for eight weeks, meaning couples do not need to plan anything.
To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email [email protected]
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.